NA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF NORTH AMERICA PSYCHEDELIC DRUGS MARKET 24
1.4 LIMITATIONS 26
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET END USER COVERAGE GRID 38
2.11 VENDOR SHARE ANALYSIS 39
2.12 SECONDARY SOURCES 40
2.13 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHT 45
4.1 PIPELINE ANALYSIS 46
4.2 PESTEL ANALYSIS 48
4.3 PORTER'S FIVE FORCES MODEL 49
5 REGULATORY FRAMEWORK: NORTH AMERICA PSYCHEDELIC DRUGS MARKET 50
5.1 REGULATORY SCENARIO IN THE U.S. 50
5.2 REGULATORY SCENARIO IN THE U.K. 51
5.3 REGULATORY SCENARIO IN INDIA 52
5.4 REGULATORY SCENARIO IN UAE 52
5.5 REGULATORY SCENARIO IN AFRICA 53
5.6 REGULATORY SCENARIO IN BRAZIL 53

6 MARKET OVERVIEW 55
6.1 DRIVERS 57
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 57
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 59
6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 62
6.1.4 ONGOING CLINICAL TRIALS 63
6.1.5 RISE IN PRODUCT APPROVALS 64
6.2 RESTRAINTS 64
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 64
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 67
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 68
6.3 OPPORTUNITIES 69
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 69
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 71
6.3.3 UPCOMING REHABILITATION CENTERS 72
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 73
6.4 CHALLENGES 73
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 73
6.4.2 RISE IN ILLEGAL ALTERNATIVES 75
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 75
7 COVID-19 IMPACT ON THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET 76
7.1 IMPACT ON PRICE 76
7.2 IMPACT ON DEMAND 76
7.3 IMPACT ON SUPPLY CHAIN 77
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 77
7.5 CONCLUSION 78
8 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY TYPE 79
8.1 OVERVIEW 80
8.2 EMPATHOGENS 83
8.3 DISSOCIATIVES 84
8.4 OTHERS 85
9 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY SOURCE 86
9.1 OVERVIEW 87
9.2 SYNTHETIC 90
9.3 NATURAL 91

10 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUGS 92
10.1 OVERVIEW 93
10.2 GAMMA-HYDROXYBUTYRIC ACID 96
10.3 KETAMINE 97
10.4 PSILOCYBIN 98
10.5 OTHERS 99
11 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION 100
11.1 OVERVIEW 101
11.2 NARCOLEPSY 104
11.3 TREATMENT RESISTANT DEPRESSION 105
11.4 MAJOR DEPRESSIVE DISORDER 106
11.5 OPIATE ADDICTION 107
11.6 POST-TRAUMATIC STRESS DISORDER 108
11.7 OTHERS 109
12 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 110
12.1 OVERVIEW 111
12.2 ORAL 114
12.3 INHALATION 115
12.4 INJECTABLE 116
13 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER 117
13.1 OVERVIEW 118
13.2 HOSPITALS 121
13.3 SPECIALTY CLINICS 122
13.4 HOMECARE 123
13.5 OTHERS 124
14 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 125
14.1 OVERVIEW 126
14.2 HOSPITALS PHARMACY 129
14.3 RETAIL PHARMACY 130
14.4 ONLINE PHARMACY 131
15 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY REGION 132
15.1 NORTH AMERICA 133
15.1.1 U.S. 140
15.1.2 CANADA 142
15.1.3 MEXICO 144
16 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 146
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 146
17 SWOT ANALYSIS 147
18 COMPANY PROFILE 148
18.1 JAZZ PHARMACEUTICALS, INC. 148
18.1.1 COMPANY SNAPSHOT 148
18.1.2 REVENUE ANALYSIS 149
18.1.3 COMPANY SHARE ANALYSIS 149
18.1.4 PRODUCT PORTFOLIO 149
18.1.5 RECENT DEVELOPMENTS 150
18.2 PFIZER INC. 151
18.2.1 COMPANY SNAPSHOT 151
18.2.2 REVENUE ANALYSIS 151
18.2.3 COMPANY SHARE ANALYSIS 152
18.2.4 PRODUCT PORTFOLIO 152
18.2.5 RECENT DEVELOPMENTS 152
18.3 F. HOFFMANN- LA ROCHE LTD 153
18.3.1 COMPANY SNAPSHOT 153
18.3.2 REVENUE ANALYSIS 153
18.3.3 COMPANY SHARE ANALYSIS 154
18.3.4 PRODUCT PORTFOLIO 154
18.3.5 RECENT DEVELOPMENT 154
18.4 JANSSEN NORTH AMERICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 155
18.4.1 COMPANY SNAPSHOT 155
18.4.2 COMPANY SHARE ANALYSIS 155
18.4.3 PRODUCT PORTFOLIO 156
18.4.4 RECENT DEVELOPMENT 156
18.5 AVADEL 157
18.5.1 COMPANY SNAPSHOT 157
18.5.2 PRODUCT PORTFOLIO 157
18.5.3 RECENT DEVELOPMENT 157
18.6 CELON PHARMA SA 158
18.6.1 COMPANY SNAPSHOT 158
18.6.2 PRODUCT PORTFOLIO 158
18.6.3 RECENT DEVELOPMENT 158

18.7 COMPASS 159
18.7.1 COMPANY SNAPSHOT 159
18.7.2 PRODUCT PORTFOLIO 159
18.7.3 RECENT DEVELOPMENTS 159
18.8 CYBIN CORP. 160
18.8.1 COMPANY SNAPSHOT 160
18.8.2 PRODUCT PORTFOLIO 160
18.8.3 RECENT DEVELOPMENTS 160
18.9 ENTHEON BIOMEDICAL CORP 161
18.9.1 COMPANY SNAPSHOT 161
18.9.2 PRODUCT PORTFOLIO 161
18.9.3 RECENT DEVELOPMENT 161
18.10 GH RESEARCH 162
18.10.1 COMPANY SNAPSHOT 162
18.10.2 PRODUCT PORTFOLIO 162
18.10.3 RECENT DEVELOPMENT 162
18.11 HIKMA PHARMACEUTICALS PLC 163
18.11.1 COMPANY SNAPSHOT 163
18.11.2 REVENUE ANALYSIS 163
18.11.3 PRODUCT PORTFOLIO 164
18.11.4 RECENT DEVELOPMENTS 164
18.12 NRX PHARMACEUTICALS, INC. 165
18.12.1 COMPANY SNAPSHOT 165
18.12.2 PRODUCT PORTFOLIO 165
18.12.3 RECENT DEVELOPMENT 165
18.13 PHARMATHER HOLDINGS LTD. 166
18.13.1 COMPANY SNAPSHOT 166
18.13.2 PRODUCT PORTFOLIO 166
18.13.3 RECENT DEVELOPMENT 166
18.14 VERRIAN 167
18.14.1 COMPANY SNAPSHOT 167
18.14.2 PRODUCT PORTFOLIO 167
18.14.3 RECENT DEVELOPMENT 167
18.15 USONAINSTITUTE.ORG 168
18.15.1 COMPANY SNAPSHOT 168
18.15.2 PRODUCT PORTFOLIO 168
18.15.3 RECENT DEVELOPMENT 168
19 QUESTIONNAIRE 169
20 RELATED REPORTS 173